Initial clinical study of indium-111-labeled clone 110 anticarcinoembryonic antigen antibody in patients with colorectal cancer.

Griffin, Thomas W.; Brill, A.B.; Stevens, Sara E.; Collins, John A.; Bokhari, Faran; Bushe, Harry; Stochl, Mark; Gionet, M.; Rusckowski, Mary; Stroupe, Stephen D.

doi:10.1200/jco.1991.9.4.631

Cited by 18 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…administration of 7D3 IgG the antibody mainly localized at the periphery of the tumour, whereas following i.v. injection the MAb predominantly localized in the interstitium and no radioactivity was seen at the periphery [19]. In our experiments, the i.v.…”

Section: Discussionmentioning

confidence: 74%

See 1 more Smart Citation

Effect of the route of administration on the biodistribution of radioiodinated OV-TL 3 F(ab′)2 in experimental ovarian cancer

et al. 1994

View full text Add to dashboard Cite

The effect of the route administration on the distribution of radioiodinated OV-TL 3 F(ab')2 was studied in Balb/c female mice with intraperitoneal or subcutaneous ovarian carcinoma xenografts. In the intraperitoneal tumour model in which both ascites and solid tumour deposits were present, intraperitoneal administration resulted in a lower estimated radiation dose to blood as compared with intravenous administration. In this model normalization to equal estimated radiation doses to blood for both routes of administration indicated that a twice as high estimated radiation dose can be guided to solid intraperitoneal tumour deposits following intraperitoneal administration. Evacuation of ascitic tumour cells prior to monoclonal antibody injection further increased the estimated radiation dose to solid intraperitoneal tumour deposits following intraperitoneal delivery. Following simultaneous intravenous and intraperitoneal injection of the monoclonal antibody, tissue uptake showed no relevant differences in the subcutaneous tumour model. Overall, the intraperitoneal route of administration was found to be the best choice for therapeutic delivery of iodine-131 labelled monoclonal antibodies.

show abstract

Section: Discussionmentioning

confidence: 74%

“…administration of 7D3 IgG to mesothelioma-bearing mice, i.p. solid tumour uptake showed no advantage for either route of administration [19]. Administration of AUA1 MAb to colon carcinoma-bearing mice showed an initial advantage for i.p.…”

Section: Discussionmentioning

confidence: 98%

Effect of the route of administration on the biodistribution of radioiodinated OV-TL 3 F(ab′)2 in experimental ovarian cancer

et al. 1994

View full text Add to dashboard Cite

show abstract

“… CEA not expressed in healthy adult human cells, except for colon lumen; tracers do not cross BBB. ( Griffin et al, 1991 ; Hammarstrom, 1999 ; Hong et al, 2008 ; Kenanova et al, 2009 ) Cell surface protein Glutamate carboxypeptidase 2 * (PSMA) PET: [ 18 F]DCFPyL, [ 18 F]DCFBC; SPECT: [ 125 I]DCFPyL; anti-PSMA antibodies can be flexibly labelled, e.g J951-IR800. Background signal in kidneys; tracers do not cross BBB.…”

Section: Rendering Cells Traceable In Vivomentioning

confidence: 99%

Cousins at work: How combining medical with optical imaging enhances in vivo cell tracking

Volpe

Kurtys

Fruhwirth

2018

The International Journal of Biochemistry & Cell Biology

View full text Add to dashboard Cite

Microscopy and medical imaging are related in their exploitation of electromagnetic waves, but were developed to satisfy differing needs, namely to observe small objects or to look inside subjects/objects, respectively. Together, these techniques can help elucidate complex biological processes and better understand health and disease. A current major challenge is to delineate mechanisms governing cell migration and tissue invasion in organismal development, the immune system and in human diseases such as cancer where the spatiotemporal tracking of small cell numbers in live animal models is extremely challenging. Multi-modal multi-scale in vivo cell tracking integrates medical and optical imaging. Fuelled by basic research in cancer biology and cell-based therapeutics, it has been enabled by technological advances providing enhanced resolution, sensitivity and multiplexing capabilities. Here, we review which imaging modalities have been successfully used for in vivo cell tracking and how this challenging task has benefitted from combining macroscopic with microscopic techniques.

show abstract

“…Tracers do not cross BBB. (Griffin et al, 1991;Hammarstrom, 1999;Hong et al, 2008;Kenanova et al, 2009) (Continued)…”

Section: Detection Sensitivity and The Duration Of Cell Trackingmentioning

confidence: 99%

How Non-invasive in vivo Cell Tracking Supports the Development and Translation of Cancer Immunotherapies

Iafrate

Fruhwirth

2020

Front. Physiol.

View full text Add to dashboard Cite

Immunotherapy is a relatively new treatment regimen for cancer, and it is based on the modulation of the immune system to battle cancer. Immunotherapies can be classified as either molecular or cell-based immunotherapies, and both types have demonstrated promising results in a growing number of cancers. Indeed, several immunotherapies representing both classes are already approved for clinical use in oncology. While spectacular treatment successes have been reported, particularly for so-called immune checkpoint inhibitors and certain cell-based immunotherapies, they have also been accompanied by a variety of severe, sometimes life-threatening side effects. Furthermore, not all patients respond to immunotherapy. Hence, there is the need for more research to render these promising therapeutics more efficacious, more widely applicable, and safer to use. Whole-body in vivo imaging technologies that can interrogate cancers and/or immunotherapies are highly beneficial tools for immunotherapy development and translation to the clinic. In this review, we explain how in vivo imaging can aid the development of molecular and cell-based anti-cancer immunotherapies. We describe the principles of imaging host T-cells and adoptively transferred therapeutic T-cells as well as the value of traceable cancer cell models in immunotherapy development. Our emphasis is on in vivo cell tracking methodology, including important aspects and caveats specific to immunotherapies. We discuss a variety of associated experimental design aspects including parameters such as cell type, observation times/intervals, and detection sensitivity. The focus is on non-invasive 3D cell tracking on the whole-body level including aspects relevant for both preclinical experimentation and clinical translatability of the underlying methodologies.

show abstract

Initial clinical study of indium-111-labeled clone 110 anticarcinoembryonic antigen antibody in patients with colorectal cancer.

Cited by 18 publications

References 0 publications

Effect of the route of administration on the biodistribution of radioiodinated OV-TL 3 F(ab′)2 in experimental ovarian cancer

Effect of the route of administration on the biodistribution of radioiodinated OV-TL 3 F(ab′)2 in experimental ovarian cancer

Cousins at work: How combining medical with optical imaging enhances in vivo cell tracking

How Non-invasive in vivo Cell Tracking Supports the Development and Translation of Cancer Immunotherapies

Contact Info

Product

Resources

About